Literature DB >> 35315259

Targeting the COP9 signalosome for cancer therapy.

Wenqi Du1,2, Ruicheng Zhang3, Bilal Muhammad3, Dongsheng Pei1.   

Abstract

The COP9 signalosome (CSN) is a highly conserved protein complex composed of 8 subunits (CSN1 to CSN8). The individual subunits of the CSN play essential roles in cell proliferation, tumorigenesis, cell cycle regulation, DNA damage repair, angiogenesis, and microenvironmental homeostasis. The CSN complex has an intrinsic metalloprotease that removes the ubiquitin-like activator NEDD8 from cullin-RING ligases (CRLs). Binding of neddylated CRLs to CSN is sensed by CSN4 and communicated to CSN5 with the assistance of CSN6, thus leading to the activation of deneddylase. Therefore, CSN is a crucial regulator at the intersection between neddylation and ubiquitination in cancer progression. Here, we summarize current understanding of the roles of individual CSN subunits in cancer progression. Furthermore, we explain how the CSN affects tumorigenesis through regulating transcription factors and the cell cycle. Finally, we discuss individual CSN subunits as potential therapeutic targets to provide new directions and strategies for cancer therapy.
Copyright © 2022 Cancer Biology & Medicine.

Entities:  

Keywords:  COP9 signalosome; cell proliferation; cullin-RING ligases; tumorigenesis; ubiquitin

Year:  2022        PMID: 35315259      PMCID: PMC9196064          DOI: 10.20892/j.issn.2095-3941.2021.0605

Source DB:  PubMed          Journal:  Cancer Biol Med        ISSN: 2095-3941            Impact factor:   5.347


  171 in total

Review 1.  Revisiting the COP9 signalosome as a transcriptional regulator.

Authors:  Daniel A Chamovitz
Journal:  EMBO Rep       Date:  2009-03-20       Impact factor: 8.807

2.  Crystal structure of the human COP9 signalosome.

Authors:  Gondichatnahalli M Lingaraju; Richard D Bunker; Simone Cavadini; Daniel Hess; Ulrich Hassiepen; Martin Renatus; Eric S Fischer; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

3.  Oncogenic Properties of Candidate Oncogenes in Chromosome Region 17p11.2p12 in Human Osteosarcoma.

Authors:  Joeri Both; Thijs Wu; Anneloor L M A Ten Asbroek; Frank Baas; Theo J M Hulsebos
Journal:  Cytogenet Genome Res       Date:  2016-11-16       Impact factor: 1.636

4.  Protein competition switches the function of COP9 from self-renewal to differentiation.

Authors:  Lei Pan; Su Wang; Tinglin Lu; Changjiang Weng; Xiaoqing Song; Joseph K Park; Jin Sun; Zhi-Hao Yang; Junjing Yu; Hong Tang; Dennis M McKearin; Daniel A Chamovitz; Jianquan Ni; Ting Xie
Journal:  Nature       Date:  2014-10-09       Impact factor: 49.962

5.  The COP9/signalosome increases the efficiency of von Hippel-Lindau protein ubiquitin ligase-mediated hypoxia-inducible factor-alpha ubiquitination.

Authors:  Yasuhiro Miyauchi; Michiko Kato; Fuminori Tokunaga; Kazuhiro Iwai
Journal:  J Biol Chem       Date:  2008-04-18       Impact factor: 5.157

6.  Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu.

Authors:  Ming-Chuan Hsu; Chee-Yin Chai; Ming-Feng Hou; Hui-Chiu Chang; Wan-Tzu Chen; Wen-Chun Hung
Journal:  Mod Pathol       Date:  2008-02-08       Impact factor: 7.842

Review 7.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

8.  microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer.

Authors:  Stephanie Geisler Crone; Anders Jacobsen; Birgitte Federspiel; Linda Bardram; Anders Krogh; Anders H Lund; Lennart Friis-Hansen
Journal:  Mol Cancer       Date:  2012-09-20       Impact factor: 27.401

9.  Knockdown of COPS3 Inhibits Lung Cancer Tumor Growth in Nude Mice by Blocking Cell Cycle Progression.

Authors:  Jianan Pang; Xu Yan; He Cao; Lei Qian; Hua He; Huimin Tian; Fujun Han; Guanjun Wang; Xiao Chen; Yuguang Zhao; Ji-Fan Hu; Jiuwei Cui
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207

10.  A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6.

Authors:  Swathi V Iyer; Tomoo Iwakuma
Journal:  Cell Cycle       Date:  2012-10-25       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.